Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma

(2021) Jin Hyun Kang et al.   BMC CANCER

904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort

(2021) A.L. Ho et al.   ANNALS OF ONCOLOGY

SO-10 An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway

(2021) M. Jung et al.   ANNALS OF ONCOLOGY

560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations

(2021) S. Crabb et al.   ANNALS OF ONCOLOGY

Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation.

(2021) Brindley Sonal Hapuarachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting RET-mutated thyroid and lung cancer in the personalised medicine era

(2021) Joanna Klubo-Gwiezdzinska   Lancet Diabetes & Endocrinology

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

(2021) Andrew X. Zhu et al.   JAMA Oncology

Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

(2021) Jingjing Sun et al.   Scientific Reports

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

(2020) R. Kurzrock et al.   ANNALS OF ONCOLOGY

ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma

(2020) Mattias K. Andersson et al.   Oncogenesis

Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase.

(2020) Chundao Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network

(2020) Alice Garrett et al.   JOURNAL OF MEDICAL GENETICS

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers

(2020) Glenn J. Hanna et al.   ONCOLOGIST

919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)

(2020) R. Ferrarotto et al.   ANNALS OF ONCOLOGY

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

(2020) M.J.M. Uijen et al.   CANCER TREATMENT REVIEWS

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

(2020) Jürgen Wolf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease

(2020) Larissa Di Villeneuve et al.   Frontiers in Oncology

The biological function and clinical significance of SF3B1 mutations in cancer

(2020) Zhixia Zhou et al.   Biomarker Research

Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class

(2020) April Weaver et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor

(2020) Kevin Kalinsky et al.   JAMA Oncology

The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma

(2020) Helen Adderley et al.   ORAL ONCOLOGY

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

(2019) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

UTX Mutations in Human Cancer

(2019) Lu Wang et al.   CANCER CELL

Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia

(2019) Raghav Dogra et al.   Anti-Cancer Agents in Medicinal Chemistry

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.

(2019) Bob T. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.

(2019) Alan Loh Ho et al.   JOURNAL OF CLINICAL ONCOLOGY

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

(2019) Dominic G. Rothwell et al.   NATURE MEDICINE

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives

(2019) Croce et al.   Cancers

Pan‐Trk immunohistochemistry is a sensitive and specific ancillary tool in diagnosing secretory carcinoma of salivary gland and detecting ETV 6‐ NTRK 3 fusion

(2019) Bin Xu et al.   HISTOPATHOLOGY

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma

(2019) Allen S. Ho et al.   JOURNAL OF CLINICAL INVESTIGATION

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

(2019) Paul V. Viscuse et al.   Frontiers in Oncology

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma

(2018) Matthew Dankner et al.   CLINICAL CANCER RESEARCH

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

(2018) Bob T. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

(2018) J Mateo et al.   ANNALS OF ONCOLOGY

Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

(2018) Hideaki Takahashi et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

(2017) Renata Ferrarotto et al.   JOURNAL OF CLINICAL ONCOLOGY

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

(2017) Marilyn M. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

(2017) Guido J.R. Zaman et al.   MOLECULAR CANCER THERAPEUTICS

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

(2017) Zhan Yao et al.   NATURE

Clinical relevance of androgen receptor alterations in prostate cancer

(2017) Emma Jernberg et al.   Endocrine Connections

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results

(2017) Michael C. Heinrich et al.   JAMA Oncology

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

(2016) J.S. de Bono et al.   ANNALS OF ONCOLOGY

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei

(2016) Magnus T. Dillon et al.   MOLECULAR CANCER THERAPEUTICS

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

(2015) Hideki Terai et al.   ACS Chemical Biology

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

(2015) Sophia X. Pfister et al.   CANCER CELL

Genomic landscape of salivary gland tumors

(2015) Shumei Kato et al.   Oncotarget

Targeting the LKB1 Tumor Suppressor

(2014) Rui-Xun Zhao et al.   CURRENT DRUG TARGETS

Targeting RAS–ERK signalling in cancer: promises and challenges

(2014) Ahmed A. Samatar et al.   NATURE REVIEWS DRUG DISCOVERY

Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: A single institutional experience at a tertiary care center

(2013) Anna Marcinow et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

(2013) S. K. Knutson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology